Bristol-Myers Squibb had another strong quarter with a particularly strong performance of its oncology drugs, Revlimid and Opdivo. After the Celgene acquisition, the pharmaceutical major’s largest chunk of revenues comes from these 2 cancer treatments and the blood thinning drug, Eliquis, which might gain excellent momentum in the coming quarters given the increasing application of blood thinners in Covid-19 treatments. Eliquis already grew by a staggering 29% in the last quarter and contributed ....
